Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Tango Therapeutics' Operating Expenses fell 1066.88% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 341.16%. This contributed to the annual value of $187.7 million for FY2024, which is 2452.82% up from last year.
  • Tango Therapeutics' Operating Expenses amounted to $39.7 million in Q3 2025, which was down 1066.88% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Operating Expenses registered a high of $49.4 million during Q2 2024, and its lowest value of $18.5 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $36.9 million, with a median of $37.0 million in 2022.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 481112881.36% in 2021, then crashed by 1068.04% in 2025.
  • Tango Therapeutics' Operating Expenses (Quarter) stood at $27.7 million in 2021, then skyrocketed by 33.49% to $37.0 million in 2022, then rose by 9.37% to $40.4 million in 2023, then increased by 11.33% to $45.0 million in 2024, then dropped by 11.74% to $39.7 million in 2025.
  • Its Operating Expenses was $39.7 million in Q3 2025, compared to $44.1 million in Q2 2025 and $47.9 million in Q1 2025.